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Patients with class 3 thalassemia with high-risk features for adverse events after high-dose chemotherapy with
hematopoietic stem cell transplantation (HSCT) are difﬁcult to treat, tending to either suffer serious toxicity or
fail to establish stable graft function. We performed HSCT in 18 such patients age 7 years and hepatomegaly
using a novel approach with pretransplant immunosuppression followed by a myeloablative reduced-toxicity
conditioning regimen (ﬂudarabine and i.v. busulfan [Flu-IV Bu]) and then HSCT. The median patient age was
14 years (range, 10 to 18 years). Before the Flu-IV Bu þ antithymocyte globulin conditioning regimen, all
patients received 1 to 2 cycles of pretransplant immunosuppression with ﬂudarabine and dexamethasone.
Thirteen patients received a related donor graft, and 5 received an unrelated donor graft. An initial prompt
engraftment of donor cells with full donor chimerism was observed in all 18 patients, but 2 patients developed
secondary mixed chimerism that necessitated withdrawal of immunosuppression to achieve full donor
chimerism. Two patients (11%) had acute grade III-IV graft-versus-host disease, and 5 patients had limited
chronic graft-versus-host disease. The only treatment-related mortality was from infection, and with a median
follow-up of 42 months (range, 4 to 75), the 5-year overall survival and thalassemia-free survival were 89%. We
conclude that this novel sequential immunoablative pretransplantation conditioning program is safe and
effective for patients with high-risk class 3 thalassemia exhibiting additional comorbidities.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is the sole available curative therapy for patients with
severe b-thalassemia, providing potential cure in approxi-
mately 80% of recipients [1]. However, several reports have
suggested the existence of a subset of patients with worse
outcomes. This subgroup includes older patients with
normal organ damage due to iron overload and/or evidence
of immunization to donor histocompatibility antigens
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U. Anurathapan et al. / Biol Blood Marrow Transplant 19 (2013) 1254e12701260through multiple blood transfusions. These patients, classi-
ﬁed by Lucarelli et al. [1] as “class 3,” demonstrate high
transplantation-related mortality (TRM; w40%) and rejec-
tion rates (w16%).
The current risk classiﬁcation of patients with severe
thalassemia who are undergoing HSCT fails to recognize
another high-risk subgroup, however: patients age 7 years
with a liver 5 cm in size. These patients constitute what
Mathews et al. [2] deﬁned as a very-high-risk subset of
a conventional high-risk class 3 group. The adverse impact of
age and liver size was further validated by a Center for Inter-
national Blood and Marrow Transplantation Research study
that summarized HSCT results at centers outside Italy and
conﬁrmed a higher TRM in patients age >7 years and those
with hepatomegaly [3]. The patients in these high-risk class 3
subsets are at elevated risk for graft rejection and regimen-
related toxicity, especially veno-occlusive disease, leading to
multiorgan failure and death. This ﬁnding stimulated the
investigation of several novel conditioning regimens [4-7].
We previously reported the use of reduced-intensity
conditioning in 8 patients with class 3 thalassemia, 6 of
whom survived thalassemia-free but 2 of whom rejected their
grafts [5]. In the present study, we wanted to test the
hypothesis that sequential pretransplant immunosuppression
(PTIS) with ﬂudarabine (Flu) and dexamethasone (Dex) before
reduced-toxicity conditioning for HSCT would safely suppress
recipient T cell function and permit sustainable engraftment
while modulating host cell-mediated antigen presentation to
alter the development of graft-versus-host disease (GVHD),
ultimately resulting in improved disease control.
PATIENTS AND METHODS
This study was approved by the Ethical Committee of the Faculty of
Medicine, Ramathibodi Hospital, Mahidol University. All patients provided
written informed consent.
Eighteen patients with severe thalassemia (14 with b-thalassemia/
hemoglobin E and 4 with homozygous b-thalassemia) treated between
December 2007 and December 2012 were included in this study. Two
(patients 3 and 4) who had undergone previous HSCT and experienced graft
rejection were enrolled for a second HSCT. The cohort included 7 males and
11 females, with a median age of 14 years (range, 10 to 18 years). All 18
patients had hepatomegaly (liver >2 cm below the costal margin [3]), and 7
had undergone splenectomy. The median ferritin level was 3100 ng/mL
(range, 869 to 8350 ng/mL). All patients were Lucarelli class 3 [1].
HLA typing was performed using a DNA-based, high-resolution tech-
nique with sequence-speciﬁc oligonucleotide primers for class I and class II
loci. Thirteen patients received a related donor graft and 5 received an
unrelated donor graft. Two of 13 patients in the related-donor group and 2 of
5 patients in the unrelated-donor group had a 1-antigen-mismatched donor
(Table 1).
Sequential Pretransplant Immunosuppression
Ten patients received 1 cycle if PTIS and 8 received 2 cycles of PTIS,
which consisted of Flu 40 mg/m2/day i.v. for 5 days and Dex 25 mg/m2/day
i.v. for 5 days. This was administered every 28 days for 1 or 2 cycles before
the start of the conditioning regimen. PTIS is given to suppress recipient T
cell function and facilitate sustainable engraftment, while decreasing the
risk of GVHD and improving disease control. Two patients in the ﬁrst 10-
patient group, who received only 1 cycle of Flu-Dex, had unstable donor
chimerism in the ﬁrst 100 days post-HSCT. Because there was no clinical
toxicity from the Flu-Dex, we administered 2 cycles, 28 days apart, in the
next 8 patients. In addition, all patients had received hydroxyurea 20mg/kg/
day daily for at least 3 months before entering our program [5].
Conditioning Regimen
The reduced-toxicity conditioning regimen consisted of ﬂudarabine
35 mg/m2 i.v. once daily for 6 days (day -9 to day -4), busulfan 130 mg/m2
i.v. once daily for 4 days (day -9 to day -6), and rabbit antithymocyte
globulin (ATG; Thymoglobulin; Sanoﬁ-Genzyme Canada, Ontario, Canada)
1.5 mg/kg/day from day -3 to day -1. This regimen was modiﬁed from
regimens described by Russell et al. [8] and de Lima et al. [9].
Figure 1. (A) Overall survival (OS) and thalassemia-free survival in 18 high-risk class 3 thalassemia patients enrolled in this study. (B) Stimulation index [the
percentage of CFSElowCD4þ T cells (with PHA) divided by the percentage CFSElowCD4þ T cells (without PHA)] from Tcell function test performed before the ﬁrst cycle of
sequential immunoablative chemotherapy (1st), before the second cycle of immunoablative chemotherapy (2nd) and before the conditioning regimen for HSCT (3rd).
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Seventeen donors received granulocyte colony-stimulating factor 10 mg/
kg/day for 5 days before the leukapheresis procedures. Peripheral blood
stem cells (PBSCs) were collected to target 5 to 10  106 CD34þ cells/kg
recipient weight. One donor donated bone marrow.
GVHD Prophylaxis
GVHD prophylaxis was started 3 days before HSCT. Patients who
received a related donor transplant were given cyclosporine, and those who
received an unrelated donor transplant were given tacrolimus. All patients
received mycophenolate mofetil from day þ1 to day þ60.
Monitoring of Chimerism
Chimerism was monitored from engraftment and every 2 weeks during
the ﬁrst 100 days after HSCT, using variable number of tandem repeats
analyses (for donorerecipient sex match) and ﬂuorescein in situ hybrid-
ization for X and Y chromosomes (for donorerecipient sex mismatch).
T Cell Function Testing
T cell function was tested by phytohemagglutination (PHA) stimulation
before and after sequential PTIS. Proliferation of T cells was detected by
a carboxyﬂuorescein diacetate succinimidyl ester (CSFE) assay as described
previously. T cell proliferation was evaluated based on a stimulation index,
which was calculated as the percentage of CFSElowCD4þ T cells with PHA
divided by the percentage of CFSElowCD4þ T cells without PHA [10].
Statistics
Survival probability was estimated by the Kaplan-Meier method.
RESULTS
Regimen-Related Toxicity, Infections, and GVHD
Four patients had grade 1-2 mucositis (22%), and 3
patients had mild, reversible veno-occlusive disease (16%).
One patient had shingles, 1 had generalized herpes zoster,
and 1 had BK virus cystitis. Another 3 patients had cyto-
megalovirus reactivation. Four patients (22%) had acute
grade II GVHD, and none had acute grade III-IV GVHD,
although both patients who experienced secondary graft
weakness and had immunosuppression held subsequently
developed acute grade III GVHD that resolved with systemic
steroid administration. Thus, the overall incidence of grade
III-IV GVHD was 11%. Five patients (28%) developed limited
chronic GVHD, and none had extensive chronic GVHD.
Engraftment and Graft Rejection
T cellereplete PBSCs were given to all but 1 patient, who
received bone marrow. The median infused cell dose was
9.4  106 CD34þ cells/kg (range, 4.67 to 19.26  106 CD34þ
cells/kg). All patients developed full donor chimerism withengraftment. Immunosuppressive treatment was successfully
weaned and discontinued by 6 months post-HSCT in the
patients who received a matched related donor graft and by
12 months post-HSCT in those who received a matched unre-
lated donor graft. However, 2 patients (patients 3 and 8)
subsequently suffered secondarymixed chimerismwithin the
ﬁrst 100 days (65% and 86% donor chimerism, respectively),
and immunesuppressionwaswithdrawn for1 to 2weeksuntil
full donor chimerism was re-established. The median time to
neutrophil engraftmentwas 12 days (range,11 to 18 days), and
that to platelet engraftmentwas 18 days (range,12 to 42 days).
Clinical Outcome
With a median follow-up of 42 months (range, 4 to
75months), the 5-year overall survival (OS) and thalassemia-
free survival (TFS) rates were both 89% (95% CI, 56% to 96%),
as shown in Figure 1A. Karnofsky/Lansky performance status
was 100% in all surviving patients at the most recent
follow-up.
Two patients (patients 3 and 8) developed secondary
mixed donor chimerism and had immunosuppression held
to allow re-establishment of full donor chimerism. The
mixed donor chimerism resolved, but the ensuing grade III
acute GVHD necessitated systemic corticosteroid adminis-
tration. Unfortunately, 1 of these patients subsequently died
of invasive pulmonary aspergillosis, and the other suffered
a lethal cerebellar hemorrhage due to an unrelated trauma
after discharge from the hospital.
T cell function tests were performed in 3 patients
(patients 14,16, and 18) who received 2 cycles of Flu-Dex. The
data suggest that T cell function was indeed signiﬁcantly
suppressed after 2 cycles of sequential PTIS. The ﬁrst assay
was performed before the initiation of Flu-Dex, and the third
assay was performed before the start of pretransplantation
conditioning (Figure 1B). We tested T cell function only in
these 3 patients because we performed this test only for the
last 5 patients in our cohort, and the blood samples from
patients 15 and 17 were missing. During ISPT, neither
infection nor neutropenia occurred, and no patient devel-
oped kidney or brain toxicity.
DISCUSSION
Matched unrelated donor HSCT is a potentially curative
option for patients with high-risk thalassemia, with clinical
outcomes comparable to those from matched sibling donor
U. Anurathapan et al. / Biol Blood Marrow Transplant 19 (2013) 1254e12701262HSCT [11]. Pretransplantation therapies include administra-
tion of hydroxyurea and azathioprine to eradicate marrow
and hypertransfusion and aggressive chelation to suppress
endogenous erythropoiesis [12,13]. Recently introduced
reduced-intensity conditioning regimens carry some
concerns regarding the risk of graft failure or rejection [11].
One of themajor risk factors for graft rejection ismixed donor
chimerism, which was found in approximately one third of
the patients [14]. Several approaches have been taken to treat
patients with mixed donor chimerism, including cessation of
immunotherapy and use of donor lymphocyte infusion.
Previous studieshave reportedTFS ratesof 50% to80%after
HSCT in patients with thalassemia with high-risk class 3
features, such as older age and hepatomegaly [2-4,6,7,15]. The
present study demonstrates that a TFS rate of approximately
90%canbeachieved.We includedpatientswithnotonlyhigh-
risk class 3 features, but also comorbidities such as diabetes
mellitus, extramedullary hematopoieisis, pulmonary hyper-
tension, andprevious splenectomy [16]; furthermore, someof
the patients received grafts from mismatched donors. With
this adverse risk information in mind, we suggest that our
approach should be consideredpromising for use in this high-
risk group. If our data are conﬁrmed, then this novel strategy
should be applied in standard-risk patients as well.
The conditioning regimen used in this studywas based on
our previously published nucleoside analog-alkylating agent
platform concept [17], providing initial immune suppression
from the nucleoside analog but with long-term stable
engraftment facilitated mostly by the alkylating agent
busulfan. We did not add irradiation, cyclophosphamide, or
other alkylating agents to the regimen. This approach may
reduce the risk for long-term toxicities, such as cardiopul-
monary toxicity and secondary malignancies, but further
study in a larger cohort is needed. The successful use of
a myeloablative, reduced-toxicity regimen is hampered to
only a minor extent by possible infertility; however, this will
be addressed in the next-generation studies using a modiﬁed
concept based on the platform described in this report.
Given that the persistence of recipient antigen-presenting
cells in the post-HSCT period could potentially increase the
risk of GVHD from the alloantigens present to donor T cells,
our sequential pretransplant immunosuppression consisting
of Flu and Dex not only suppresses recipient T cell function
and facilitates sustainable engraftment, but also ensures the
complete elimination of recipient antigen-presenting cells.
Moreover, Flu-containing conditioning regimens, including
the conditioning regimen used in this study (Flu, busulfan,
and ATG) are reportedly associated with a decreased inci-
dence of GVHD [18,19].
In conclusion, a key success factor in our safe and efﬁca-
cious program is the sequential use of pretransplant immu-
nosuppression followed by a reduced-toxicity conditioning
program rather than striving for maximum intensity of the
conditioning program itself, paired with a relatively high
number of hematopoietic progenitor cells (on average >5 
106 CD34þ cells/ kg of recipientweight [5,20]),which resulted
in a low incidence of toxicity and durable engraftment in this
group of patients with high-risk class 3 thalassemia.
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